Hide metadata

dc.contributor.authorBarfeld, Stefan J
dc.contributor.authorEast, Philip
dc.contributor.authorZuber, Verena
dc.contributor.authorMills, Ian G
dc.date.accessioned2015-10-20T12:48:28Z
dc.date.available2015-10-20T12:48:28Z
dc.date.issued2014
dc.identifier.citationBMC Medical Genomics. 2014 Dec 31;7(1):513
dc.identifier.urihttp://hdl.handle.net/10852/47421
dc.description.abstractBackground Tumorigenesis is characterised by changes in transcriptional control. Extensive transcript expression data have been acquired over the last decade and used to classify prostate cancers. Prostate cancer is, however, a heterogeneous multifocal cancer and this poses challenges in identifying robust transcript biomarkers. Methods In this study, we have undertaken a meta-analysis of publicly available transcriptomic data spanning datasets and technologies from the last decade and encompassing laser capture microdissected and macrodissected sample sets. Results We identified a 33 gene signature that can discriminate between benign tissue controls and localised prostate cancers irrespective of detection platform or dissection status. These genes were significantly overexpressed in localised prostate cancer versus benign tissue in at least three datasets within the Oncomine Compendium of Expression Array Data. In addition, they were also overexpressed in a recent exon-array dataset as well a prostate cancer RNA-seq dataset generated as part of the The Cancer Genomics Atlas (TCGA) initiative. Biologically, glycosylation was the single enriched process associated with this 33 gene signature, encompassing four glycosylating enzymes. We went on to evaluate the performance of this signature against three individual markers of prostate cancer, v-ets avian erythroblastosis virus E26 oncogene homolog (ERG) expression, prostate specific antigen (PSA) expression and androgen receptor (AR) expression in an additional independent dataset. Our signature had greater discriminatory power than these markers both for localised cancer and metastatic disease relative to benign tissue, or in the case of metastasis, also localised prostate cancer. Conclusion In conclusion, robust transcript biomarkers are present within datasets assembled over many years and cohorts and our study provides both examples and a strategy for refining and comparing datasets to obtain additional markers as more data are generated.
dc.language.isoeng
dc.relation.ispartofBarfeld, Stefan J. (2015) The transcriptional role of c-Myc in prostate cancer. Doctoral thesis. http://urn.nb.no/URN:NBN:no-52192
dc.relation.urihttp://urn.nb.no/URN:NBN:no-52192
dc.rightsBarfeld et al.; licensee BioMed Central.
dc.rightsAttribution 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.titleMeta-analysis of prostate cancer gene expression data identifies a novel discriminatory signature enriched for glycosylating enzymes
dc.typeJournal article
dc.date.updated2015-10-20T12:48:29Z
dc.creator.authorBarfeld, Stefan J
dc.creator.authorEast, Philip
dc.creator.authorZuber, Verena
dc.creator.authorMills, Ian G
dc.identifier.cristin1205923
dc.identifier.doihttp://dx.doi.org/10.1186/s12920-014-0074-9
dc.identifier.urnURN:NBN:no-51522
dc.type.documentTidsskriftartikkel
dc.type.peerreviewedPeer reviewed
dc.identifier.fulltextFulltext https://www.duo.uio.no/bitstream/handle/10852/47421/1/12920_2014_Article_74.pdf
dc.type.versionPublishedVersion
cristin.articleid513


Files in this item

Appears in the following Collection

Hide metadata

Attribution 4.0 International
This item's license is: Attribution 4.0 International